[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 399 9500", "website": "https://www.tscan.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 175, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gavin  MacBeath Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 853513, "exercisedValue": 0, "unexercisedValue": 471064}, {"maxAge": 1, "name": "Dr. Zoran  Zdraveski J.D., Ph.D.", "age": 53, "title": "Chief Legal & Strategy Officer and Company Secretary", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 657200, "exercisedValue": 0, "unexercisedValue": 85247}, {"maxAge": 1, "name": "Dr. Stephen J. Elledge Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tomasz  Kula Ph.D.", "title": "Co-Founder & Member of Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason A. Amello", "age": 55, "title": "CFO & Treasurer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Justin  McCue Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Hargraves", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shrikanta  Chattopadhyay M.D.", "title": "Senior VP & Head of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ray  Lockard M.B.A.", "title": "Senior Vice President & Head of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jim  Murray", "title": "Senior VP & Head of Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.54, "open": 4.61, "dayLow": 4.58, "dayHigh": 5.0999, "regularMarketPreviousClose": 4.54, "regularMarketOpen": 4.61, "regularMarketDayLow": 4.58, "regularMarketDayHigh": 5.0999, "beta": 0.765, "forwardPE": -3.8372092, "volume": 222728, "regularMarketVolume": 222728, "averageVolume": 204157, "averageVolume10days": 163500, "averageDailyVolume10Day": 163500, "bid": 4.92, "ask": 5.0, "bidSize": 100, "askSize": 100, "marketCap": 262220800, "fiftyTwoWeekLow": 3.73, "fiftyTwoWeekHigh": 9.69, "priceToSalesTrailing12Months": 21.493507, "fiftyDayAverage": 5.3582, "twoHundredDayAverage": 6.6069, "currency": "USD", "enterpriseValue": 55617656, "floatShares": 25676435, "sharesOutstanding": 48697300, "sharesShort": 2244117, "sharesShortPriorMonth": 1796710, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0424, "heldPercentInsiders": 0.00883, "heldPercentInstitutions": 0.99601996, "shortRatio": 10.64, "shortPercentOfFloat": 0.0587, "bookValue": 4.822, "priceToBook": 1.0265449, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -104413000, "trailingEps": -0.65, "forwardEps": -1.29, "enterpriseToRevenue": 4.559, "enterpriseToEbitda": -0.521, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TCRX", "underlyingSymbol": "TCRX", "shortName": "TScan Therapeutics, Inc.", "longName": "TScan Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "78cfed2a-5d5f-3a28-9bf2-d5f7bc0c36ba", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.95, "targetHighPrice": 15.0, "targetLowPrice": 10.0, "targetMeanPrice": 12.57, "targetMedianPrice": 12.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 297676000, "totalCashPerShare": 5.619, "ebitda": -106656000, "totalDebt": 91073000, "quickRatio": 7.717, "currentRatio": 7.765, "totalRevenue": 12200000, "debtToEquity": 35.684, "revenuePerShare": 0.23, "returnOnAssets": -0.20164, "returnOnEquity": -0.4684, "freeCashflow": -38216624, "operatingCashflow": -71241000, "revenueGrowth": -0.83, "operatingMargins": -63.64552, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-04"}]